Internalization of therapeutic antibodies into dendritic cells as a risk factor for immunogenicity
Michel Siegel(Roche (Switzerland)), Thomas E. Kraft(Roche Pharma AG (Germany)), Katharina Hartman(Roche (Switzerland)), Cary M. Looney(Roche (Switzerland)), Céline Marban-Doran(Roche (Switzerland)), Axel Ducret(Roche (Switzerland)), Hubert Kettenberger(Roche Pharma AG (Germany)), Timothy P. Hickling(Roche (Switzerland)), Olivier Rohr(Centre National de la Recherche Scientifique), Martin Lechmann(Roche (Switzerland)), Johannes Fraidling(Roche Pharma AG (Germany)), Anna‐Lena Bolender(Roche Pharma AG (Germany))
Cited by 7
Related Papers
Independent evolution of the prochlorophyte and green plant chlorophyll <i>a/b</i> light-harvesting proteins
|Proceedings of the National Academy of Sciences|1996|234
Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection
|Proceedings of the National Academy of Sciences|2003|170
Immunopurification and Mass Spectrometric Quantification of the Active Form of a Chimeric Therapeutic Antibody in Human Serum
|Analytical Chemistry|2008|144
Vaccination trial with HPV16 L1E7 chimeric virus‐like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3)
|International Journal of Cancer|2007|136